Eagle Pharmaceuticals Operating Income 2013-2023 | EGRX

Eagle Pharmaceuticals operating income from 2013 to 2023. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.

Eagle Pharmaceuticals Operating Income 2013-2023 | EGRX

Eagle Pharmaceuticals operating income from 2013 to 2023. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$205.5B
Stryker (SYK)$138.7B
Boston Scientific (BSX)$121.5B
Medtronic (MDT)$113.7B
EssilorLuxottica (ESLOY)$104.2B
Haleon (HLN)$48.6B
Lonza Group Ag (LZAGY)$45.9B
ResMed (RMD)$36.9B
Koninklijke Philips (PHG)$29.3B
Terumo (TRUMY)$27.8B
Zimmer Biomet Holdings (ZBH)$21.6B
Baxter (BAX)$20.3B
Insulet (PODD)$16.5B
Smith & Nephew SNATS (SNN)$13.5B
Bio-Rad Laboratories (BIO)$9.3B
Demant (WILYY)$9.2B
BellRing Brands (BRBR)$7.7B
Lantheus Holdings (LNTH)$7.3B
ICU Medical (ICUI)$4.3B
Haemonetics (HAE)$3.9B
TG Therapeutics (TGTX)$3.9B
GN Store Nord (GNNDY)$3.8B
Perrigo (PRGO)$3.8B
Neogen (NEOG)$3.7B
Prestige Consumer Healthcare (PBH)$3.6B
Envista Holdings (NVST)$3.3B
QuidelOrtho (QDEL)$3.1B
Agios Pharmaceuticals (AGIO)$2.6B
Maravai LifeSciences Holdings (MRVI)$2.3B
Green Thumb Industries (GTBIF)$2.2B